Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3
| Autor: | Valentina Andreasi, Andreas Pascher, Felix J. Krendl, Claudio Doglioni, Stefano Partelli, Bertram Wiedenmann, Ruza Arsenic, Marianne Pavel, Stefan Staettner, Thomas M. Gress, Daniel Kaemmerer, Anja Rinke, Massimo Falconi, Elettra Merola |
|---|---|
| Přispěvatelé: | Merola, E., Falconi, M., Rinke, A., Staettner, S., Krendl, F., Partelli, S., Andreasi, V., Gress, T. M., Pascher, A., Arsenic, R., Doglioni, C., Kaemmerer, D., Wiedenmann, B., Pavel, M. E. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Population Neuroendocrine neoplasms G3 030209 endocrinology & metabolism 03 medical and health sciences 0302 clinical medicine Recurrence medicine Overall survival Humans Radical surgery education Stage IV Aged Neoplasm Staging Retrospective Studies Curative intent Chemotherapy education.field_of_study business.industry Standard treatment Patient Selection General Medicine Middle Aged Surgery Survival Rate Neuroendocrine Tumors 030220 oncology & carcinogenesis Female Neoplasm Grading Neoplasm Recurrence Local business Radical resection Stage iv |
| Popis: | Background Stage IV gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) G3 are the NENs with the worst prognosis. According to ENETS guidelines, platinum-based chemotherapy is the standard treatment for this population. Surgery is only considered in highly selected “resectable” NENs with usually lower Ki67. However, the role of surgery with curative intent has been poorly investigated. Objective To describe, in a retrospective series of stage IV GEP-NENs G3, overall survival (OS) and recurrence-free survival (RFS) rates after curatively intended surgery. Methods Multicenter analysis of stage IV GEP-NENs G3 receiving radical resection (R0/R1) from 2007 to 2017, with minimum post-surgical follow-up time of 3 months. Results Fifteen patients from 6 NEN referral centers, with median follow-up of 29 months (8-86), were included. Eight cases had a neuroendocrine carcinoma (NEC) and 7 a neuroendocrine tumor G3 (NET G3). Median OS after radical surgery was 59 months. All patients recurred, with a median RFS of 8 months. Conclusions Radical surgery might be considered for highly selected stage IV GEP-NENs G3. Larger series are needed to confirm these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|